Linked Life Data

15670545

Source:http://linkedlifedata.com/resource/pubmed/id/15670545

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-1-26
pubmed:abstractText
The metabolic syndrome (MS) is a constellation of coronary risk factors. Atherogenic dyslipidemia is an important factor in cardiovascular risk in these patients, and treatment of atherogenic dyslipidemia has been identified as an important goal of therapy in patients with MS. This post hoc analysis of data from a 6-week, randomized, open-label, parallel-group, comparative trial (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin [STELLAR]) assessed the effects of rosuvastatin 10, 20, and 40 mg, atorvastatin 10, 20, 40, and 80 mg, simvastatin 10, 20, 40, and 80 mg, and pravastatin 10, 20, and 40 mg on plasma lipids in hypercholesterolemic patients (low-density lipoprotein cholesterol >/=160 and <250 mg/dl; triglycerides <400 mg/dl) who had >/=3 of the 5 National Cholesterol Education Program Adult Treatment Panel III criteria for MS (body mass index >30 kg/m(2) substituted for waist circumference). Of 2,268 patients, 811 met criteria for MS. Percent reductions in low-density lipoprotein cholesterol ranged from 20% in the pravastatin 10-mg group to 55% in the rosuvastatin 40-mg group. In patients with MS, triglyceride reductions were 22% to 34% with rosuvastatin, 23% to 33% with atorvastatin, 15% to 23% with simvastatin, and 12% to 15% with pravastatin. High-density lipoprotein cholesterol increased by 8% to 11% with rosuvastatin, 5% to 9% with atorvastatin, 8% to 10% with simvastatin, and 3% to 7% with pravastatin. Rosuvastatin, atorvastatin, simvastatin, and pravastatin treatment had favorable effects in hypercholesterolemic patients on the atherogenic dyslipidemia associated with MS. Rosuvastatin had the most favorable effect on the atherogenic lipid profile of MS overall.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
360-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15670545-Adult, pubmed-meshheading:15670545-Aged, pubmed-meshheading:15670545-Aged, 80 and over, pubmed-meshheading:15670545-Arteriosclerosis, pubmed-meshheading:15670545-Female, pubmed-meshheading:15670545-Fluorobenzenes, pubmed-meshheading:15670545-Heptanoic Acids, pubmed-meshheading:15670545-Humans, pubmed-meshheading:15670545-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:15670545-Hyperlipidemias, pubmed-meshheading:15670545-Male, pubmed-meshheading:15670545-Metabolic Syndrome X, pubmed-meshheading:15670545-Middle Aged, pubmed-meshheading:15670545-Pravastatin, pubmed-meshheading:15670545-Pyrimidines, pubmed-meshheading:15670545-Pyrroles, pubmed-meshheading:15670545-Simvastatin, pubmed-meshheading:15670545-Sulfonamides, pubmed-meshheading:15670545-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
pubmed:affiliation
VA Central California Health Care System and University of California-San Francisco, Fresno, California, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study